Cost of US prescription drug plan could surge
CONGRESSIONAL budget analysts told US lawmakers last week that the cost of providing prescription drugs to seniors on Medicare could top $1 trillion over 10 years, seven times more than President Bush has budgeted and far more than Democrats have proposed.
Ivax earnings boosted on strong sales of Onxol
Ivax Corp, which makes generic and branded drugs, said it expects its first-quarter earnings to exceed analysts’ expectations due to strong sales of the cancer treatment Onxol.
ICC wins Sanofi-Synthelabo business
INTEGRATED Communications Corporation (ICC), one of the nation’s leading healthcare advertising agencies, announced that it has been selected by Sanofi-Synthelabo as global agency of record for Rasburicase, its recombinant urate oxidase product.
Purdue sues Endo over Oxycontin patents
ENDO Pharmaceuticals holdings Inc, a fully integrated, specialty pharmaceutical company with market leadership in pain management
Roche seeks approval to use Xenical for diabetes
HOFFMANN-La Roche Inc submitted a supplemental application to the Food and Drug Administration for its weight loss drug Xenical (orlistat) to improve glycaemic control when used as an adjunct to other antidiabetic treatments in overweight or obese patients with type 2 diabetes.
Barr Labs gets FDA OK for Methotrexate tabs
BARR Laboratories Inc has received the US Food & Drug Administration (FDA) approval for its proprietary methotrexate tablets usp, 5, 7.5, 10 and 15 mg. This represents the second Barr proprietary product approved by FDA this year.